These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 26547678)

  • 21. Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan.
    Nakamura M; Yamada N; Ito M
    J Atheroscler Thromb; 2017 Jun; 24(6):560-565. PubMed ID: 28392512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Target-specific Oral Anticoagulants in the Emergency Department.
    Peacock WF; Levy PD; Gonzalez MG; Than M
    J Emerg Med; 2016 Feb; 50(2):246-57. PubMed ID: 26614713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Target-specific oral anticoagulants and the hospitalist.
    Deitelzweig S; Amin A
    Hosp Pract (1995); 2015; 43(1):1-12. PubMed ID: 25559350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overview of the new oral anticoagulants: opportunities and challenges.
    Yeh CH; Hogg K; Weitz JI
    Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1056-65. PubMed ID: 25792448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant.
    Arachchillage DR; Besser M; Maclean R; Baglin T; van Veen JJ
    Thromb Res; 2016 Jul; 143():137-40. PubMed ID: 27244105
    [No Abstract]   [Full Text] [Related]  

  • 26. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct oral anticoagulants for use in paediatrics.
    Jaffray J; Young G
    Lancet Child Adolesc Health; 2022 Mar; 6(3):207-214. PubMed ID: 35033222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.
    Vanassche T; Vandenbriele C; Peerlinck K; Verhamme P
    Expert Opin Pharmacother; 2015 Apr; 16(5):645-58. PubMed ID: 25554350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New - direct oral anticoagulants: actual review].
    Michalcová J; Penka M; Buliková A; Zavřelová J; Štěpařová A
    Vnitr Lek; 2016; 62(10):805-813. PubMed ID: 27900867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
    Meddahi S; Samama MM
    J Mal Vasc; 2014 May; 39(3):183-94. PubMed ID: 24650612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: a real-world single-center study.
    Badreldin H
    J Thromb Thrombolysis; 2018 Jul; 46(1):16-21. PubMed ID: 29626281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
    Feng W; Wu K; Liu Z; Kong G; Deng Z; Chen S; Wu Y; Chen M; Liu S; Wang H
    Thromb Res; 2015 Dec; 136(6):1133-44. PubMed ID: 26498222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiology Patient Pages: Antidotes for Bleeding Caused by Novel Oral Anticoagulants.
    Pollack CV
    Circulation; 2016 Jan; 133(2):e18-9. PubMed ID: 27028439
    [No Abstract]   [Full Text] [Related]  

  • 34. New anticoagulants for the treatment of venous thromboembolism.
    Prandoni P; Dalla Valle F; Piovella C; Tormene D; Pesavento R
    Minerva Med; 2013 Apr; 104(2):131-39. PubMed ID: 23514989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term benefits of preventing venous thromboembolic events.
    Cohen AT
    Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes.
    Imberti D; Mastroiacovo D
    Intern Emerg Med; 2017 Aug; 12(5):561-563. PubMed ID: 28647891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modern Treatment Modalities and Duration of Treatment for Venous Thromboembolism.
    Robert-Ebadi H; Righini M
    Ther Umsch; 2016; 73(10):618-625. PubMed ID: 28045360
    [No Abstract]   [Full Text] [Related]  

  • 38. Venous thromboembolism management: where do novel anticoagulants fit?
    Spyropoulos AC; Turpie AG
    Curr Med Res Opin; 2013 Jul; 29(7):783-90. PubMed ID: 23659584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of factor Xa inhibitors in venous thromboembolism treatment.
    Cabral KP; Ansell JE
    Vasc Health Risk Manag; 2015; 11():117-23. PubMed ID: 25673997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct oral anticoagulants in rare venous thrombosis.
    Finazzi G; Ageno W
    Intern Emerg Med; 2016 Mar; 11(2):167-70. PubMed ID: 26875179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.